Selank and Immune Function: The Anxiety-Immunity Link
Selank
34 genes
A single injection of the tuftsin analog Selank altered expression of 34 out of 84 inflammation-related genes in the mouse spleen within 24 hours.
Kolomin et al., Regulatory Peptides, 2011
Kolomin et al., Regulatory Peptides, 2011
View as imageSelank was built to treat anxiety. It ended up rewriting the immune system's gene expression profile. When Russian researchers at the Institute of Molecular Genetics injected mice with this synthetic tuftsin analog and then checked their spleens, they found significant expression changes in 34 of the 84 inflammation-related genes they tested.[1] That result turned Selank from a straightforward anxiolytic peptide into something more complicated: a molecule that sits at the intersection of the nervous system and the immune system. For the full picture of what Selank is and how it works, see our comprehensive Selank overview.
Key Takeaways
- A single Selank injection (100 mcg/kg) altered expression of 34 out of 84 inflammation-related genes in the mouse spleen within 24 hours (Kolomin et al., 2011)
- Under social stress, Selank reduced elevated IL-1 beta, IL-6, and TNF-alpha nearly to baseline levels in animal models (Leonidovna et al., 2021)
- The complement component C3 gene showed a 3-fold decrease in mRNA within 3 hours of Selank administration, then rebounded by 24 hours (Kolomin et al., 2014)
- Selank upregulated Bcl6, a master transcription factor that controls B-cell differentiation and immune system development (Kolomin et al., 2011)
- Selank's parent molecule tuftsin is a natural fragment of immunoglobulin G that activates phagocytes, and the synthetic extension preserves this immune signaling capacity (Kozlovskaya et al., 2003)
- Tuftsin-based nanoparticles rejuvenated dysfunctional macrophages and improved survival in a preclinical sepsis model, confirming the core molecule's immune relevance (Qing et al., 2025)
From tuftsin to Selank: why an immune peptide became an anxiolytic
Selank's immune story starts with its parent molecule. Tuftsin (Thr-Lys-Pro-Arg) is a tetrapeptide fragment cleaved from the Fc region of immunoglobulin G, the most abundant antibody in human blood.[2] In the body, tuftsin activates phagocytic cells: macrophages, monocytes, and neutrophils. It stimulates them to engulf bacteria, produce reactive oxygen species, and release cytokines. It is, at its core, an immune activation signal.
Researchers at the Institute of Molecular Genetics extended tuftsin by adding three amino acids (Pro-Gly-Pro) to its C-terminus, creating the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. The extension improved metabolic stability; the original tuftsin degrades within minutes in blood plasma, while the Selank version resists enzymatic breakdown long enough to produce measurable neurological effects.[3] The anxiolytic properties were the intended application. The immune effects were inherited from tuftsin, and for years they were treated as a secondary finding.
That changed when gene expression studies revealed just how broadly Selank reshapes immune signaling.
34 inflammation genes altered in the spleen
Kolomin and colleagues (2011) gave mice a single intraperitoneal injection of Selank at 100 mcg/kg and measured mRNA levels for 84 inflammation-related genes in spleen tissue at 6 and 24 hours.[1] These 84 genes covered chemokines, cytokines, their receptors, and related signaling molecules.
The results: 34 of 84 genes showed statistically significant expression changes. The most pronounced shifts occurred in five genes:
- Bcl6: upregulated. This transcription factor is essential for germinal center B-cell formation, T-follicular helper cell differentiation, and memory B-cell development. It plays what the authors described as a "main role in the formation and development of the immune system."
- C3: the third component of the complement cascade, which marks pathogens for destruction. Expression decreased sharply.
- Casp1: caspase-1, the enzyme that processes pro-IL-1 beta and pro-IL-18 into their active inflammatory forms.
- Il2rg: the common gamma chain shared by receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Changes here affect multiple cytokine signaling pathways simultaneously.
- Xcr1: a chemokine receptor expressed on dendritic cells involved in cross-presentation of antigens to CD8+ T cells.
Selank also affected two of its own fragments. When the researchers tested the Gly-Pro dipeptide fragment and the Thr-Lys-Pro-Arg (tuftsin) fragment separately, each produced its own distinct gene expression signature.[1] This means the full Selank molecule is not simply tuftsin with a stability tag. The extension changes the immunological profile.
For readers interested in how other peptides modulate immune transcription factors, thymosin alpha-1 works through a different mechanism but shares the theme of peptide-driven immune gene regulation.
The temporal dynamics: fast suppression, then rebalancing
A follow-up study by the same group (Kolomin et al., 2014) tracked how the gene expression changes unfolded over time.[4] They focused on four of the most affected genes (C3, Casp1, Il2rg, Xcr1) and measured mRNA levels at 1, 3, 6, and 24 hours after Selank injection.
The complement gene C3 showed the most dramatic pattern: a 3-fold decrease in mRNA at 3 hours, followed by a return toward baseline by 24 hours. The Gly-Pro fragment produced a different temporal profile for the same genes, suggesting that the full-length Selank molecule and its metabolic breakdown products create a layered, time-dependent immune response.
This two-phase pattern, rapid suppression followed by normalization, is not what you see with broad immunosuppressants like corticosteroids, which push everything down and keep it down. It looks more like the immune system being reset to a different set point, then allowed to find its own equilibrium. Whether this pattern holds in tissues beyond the spleen, or in humans rather than mice, remains untested.
Cytokine normalization under stress
The link between Selank's anxiolytic and immune effects becomes clearest in the 2021 study by Leonidovna and colleagues, which measured cytokine levels under "social" stress conditions.[5]
Social stress in animal models elevates pro-inflammatory cytokines. This is not unique to rodents; decades of human psychoneuroimmunology research confirm that chronic psychological stress increases circulating IL-6, TNF-alpha, and IL-1 beta in people. The question was whether Selank's anxiolytic effects would also normalize the immune disruption that accompanies stress.
The answer was yes, at least in the animal model. Selank reduced stress-elevated concentrations of IL-1 beta, IL-6, and TNF-alpha nearly to control values. It also affected TGF-beta-1, a pleiotropic cytokine involved in both immune suppression and tissue repair.
This is the core finding that makes the anxiety-immunity link concrete. Stress disrupts immune function. Selank reduces anxiety-like behavior through GABA modulation and serotonin system effects. And it simultaneously normalizes the cytokine disruption that stress produces. Whether these are two separate pharmacological actions or a single mechanism with dual outputs is an open question.
The GABA connection to immune gene expression
Selank's anxiolytic mechanism runs through the GABAergic system. Filatova and colleagues (2017) showed that Selank alters expression of genes involved in GABA neurotransmission in IMR-32 neuroblastoma cells, with effects comparable to those of GABA itself and the antipsychotic olanzapine.[6]
This matters for the immune story because GABA receptors are not confined to the brain. They are expressed on T cells, macrophages, dendritic cells, and other immune cells. GABA signaling in immune cells generally suppresses pro-inflammatory responses. So when Selank enhances GABAergic tone, it may simultaneously calm neural circuits (reducing anxiety) and dampen immune cell activation (reducing inflammation).
The Kasian et al. (2017) study adds another layer: when Selank was combined with diazepam (a classical benzodiazepine) in chronically stressed rats, the combination was more effective at reducing anxiety than either compound alone.[7] Whether this synergy extends to immune outcomes has not been studied, but the enhanced GABAergic activation suggests it could.
For comparison, neuropeptide Y operates through a different receptor system but shows a similar dual profile: stress resilience on the neural side, immune modulation on the peripheral side.
BDNF, neuroplasticity, and immune crosstalk
Selank's effects extend beyond classical immune molecules. Kolik and colleagues (2019) demonstrated that Selank (0.3 mg/kg/day for 7 days) prevented ethanol-induced memory impairment in rats and regulated brain-derived neurotrophic factor (BDNF) levels in both the hippocampus and prefrontal cortex.[8]
BDNF is primarily known as a neuroplasticity factor, but it also modulates immune function. BDNF receptors are present on macrophages and lymphocytes. In the gut, BDNF influences mucosal immunity. In the brain, BDNF-dependent neuroplasticity affects the hypothalamic-pituitary-adrenal (HPA) axis, which is the primary neuroendocrine regulator of immune function.
The ethanol model is relevant because chronic alcohol exposure simultaneously impairs both cognition and immune function. Selank's ability to protect BDNF levels in this context suggests a neuroprotective mechanism that could have downstream immune consequences, though direct immune measurements were not part of this study.
Tuftsin's immune legacy: from phagocytes to sepsis
The most direct evidence for the immune potency of Selank's core molecular scaffold comes from recent work on tuftsin itself. Qing et al. (2025) published in Science Translational Medicine a study describing "BATMAN" (bacteria-targeted transformable macrophage nanorejuvenator), a self-assembling peptide nanoparticle built around tuftsin clusters.[9]
In their preclinical sepsis model, these tuftsin-based nanoparticles rejuvenated dysfunctional macrophages, restoring their ability to phagocytose bacteria and clear secondary infections. The results confirmed what immunologists have known since the 1970s: tuftsin is a genuine immune activator, not a minor signaling molecule.
This 2025 work validates the foundation on which Selank is built. Selank inherited tuftsin's phagocyte-activating properties, then gained additional anxiolytic and gene-regulatory activities through its C-terminal extension. The immune effects are not a side note; they are baked into the molecular structure.
What this evidence does not show
The immune research on Selank has real limitations that need to be stated directly:
No human immune data exists. Every gene expression and cytokine study described above was conducted in mice. The 2021 stress-cytokine study used a rodent social stress model. While Russian clinical studies have tested Selank for anxiety in humans, those trials measured anxiety scores and neurotransmitter markers, not immune parameters. The gene expression changes seen in mouse spleens may or may not translate to human immune organs.
Dose-response relationships are unclear. Most studies used a single dose (100 mcg/kg intraperitoneally in mice). Whether lower or higher doses produce different immune profiles, whether chronic dosing maintains or alters the acute response, and whether intranasal delivery (the common human route) reaches immune tissues in relevant concentrations are all unanswered questions.
Mechanism vs. outcome. Changing gene expression is not the same as changing immune function in a way that matters clinically. A 3-fold decrease in C3 mRNA does not tell you whether complement-mediated bacterial killing is affected. Normalizing cytokines in stressed mice does not tell you whether a human with chronic anxiety would see fewer infections, better vaccine responses, or any other functional immune improvement.
The research base is narrow. Nearly all Selank studies come from a small number of Russian research groups, primarily at the Institute of Molecular Genetics. Independent replication by labs outside this network is limited. This is not unusual for Russian-developed peptides, but it means the evidence has not been tested against different experimental cultures, methods, and biases.
The broader picture: peptides at the neuro-immune border
Selank is not the only peptide that bridges anxiety and immunity. The field of psychoneuroimmunology has documented dozens of molecules that operate in both systems. KPV, derived from alpha-melanocyte-stimulating hormone, suppresses NF-kB-driven inflammation. Thymosin alpha-1 directly matures T cells and has been tested in viral infections. Nootropic peptides as a class often show secondary immune effects that are understudied relative to their cognitive actions.
What makes Selank unusual is the specificity of the evidence. Rather than vague claims about "immune support," the Kolomin studies provide exact gene names, fold-change values, and temporal profiles. The Leonidovna study provides specific cytokine measurements under defined stress conditions. The molecular story is detailed enough to generate testable predictions, which is how real pharmacology advances.
Whether those predictions will hold up in human studies remains to be seen. The mouse spleen is not a human lymph node. But the data is specific, reproducible within the groups that have tested it, and consistent with what we know about tuftsin biology. For a peptide originally designed to treat anxiety, that is a substantial body of immunological evidence.
The Bottom Line
Selank, a synthetic extension of the immune-activating peptide tuftsin, alters expression of 34 inflammation-related genes in the mouse spleen, normalizes stress-elevated cytokines (IL-1 beta, IL-6, TNF-alpha) in animal models, and shows temporal gene regulation patterns that suggest immune rebalancing rather than simple suppression. All immune data comes from animal studies, primarily from Russian research groups. No human trials have measured Selank's immune effects directly, and the clinical significance of the observed gene expression changes remains unestablished.